PacBio supports a study showcasing advanced sequencing techniques to identify genetic causes of a complex Mendelian condition.
Quiver AI Summary
PacBio announced its involvement in a groundbreaking study published in Nature Genetics, which utilized its advanced sequencing technology to explore the genetic basis of a rare Mendelian condition in a 9-month-old patient. Collaborating with the University of Washington and the Undiagnosed Diseases Network, researchers employed PacBio's multiomic approach, integrating genome, methylome, epigenome, and transcriptome data using the Revio™ sequencing system. This innovative method identified a chromosome X;13 balanced translocation affecting four key genes, revealing various pathogenic mechanisms. The study underscores the transformative potential of PacBio's long-read sequencing technology in diagnosing complex genetic diseases, paving the way for improved patient outcomes in genomic medicine.
Potential Positives
- PacBio played a critical role in a significant study published in Nature Genetics, showcasing the effectiveness of its advanced sequencing solutions in resolving a Mendelian condition.
- The study demonstrated the successful application of PacBio's Revio™ sequencing system and innovative multiomic solutions, leading to the identification of complex genetic disruptions that traditional methods could not resolve.
- This collaboration with prestigious institutions like the University of Washington and the Undiagnosed Diseases Network emphasizes PacBio's leadership and credibility in the genomics field.
- The findings from this research highlight how PacBio's technology can facilitate transformational advancements in the diagnosis and treatment of rare genetic diseases, potentially broadening the application of its products in clinical settings.
Potential Negatives
- None
FAQ
What is the main focus of the study published in Nature Genetics?
The study focuses on resolving a Mendelian condition using PacBio's long-read sequencing technology and multiomic analysis.
How did PacBio's technology contribute to the study's findings?
PacBio's advanced sequencing solutions enabled simultaneous analysis of genomic, transcriptomic, methylomic, and epigenomic data, revealing complex genetic mechanisms.
What is the significance of synchronized multiomic sequencing?
Synchronized multiomic sequencing allows for comprehensive insights in a single run, eliminating redundant experiments and providing a complete genomic picture.
Who collaborated on this research study?
PacBio collaborated with the University of Washington and the Undiagnosed Diseases Network to conduct this groundbreaking research.
What are the potential applications of the Revio system in genomics?
The Revio system aims to enhance the diagnosis and treatment of rare genetic diseases, advancing research capabilities in various fields.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PACB Insider Trading Activity
$PACB insiders have traded $PACB stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $PACB stock by insiders over the last 6 months:
- CHRISTIAN O HENRY (See Remarks) sold 98,907 shares for an estimated $172,691
- OENE MARK VAN (See Remarks) has made 0 purchases and 2 sales selling 72,416 shares for an estimated $133,154.
- JEFF EIDEL (See Remarks) sold 26,760 shares for an estimated $42,601
- SUSAN G. KIM (See Remarks) sold 19,782 shares for an estimated $34,064
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PACB Hedge Fund Activity
We have seen 87 institutional investors add shares of $PACB stock to their portfolio, and 102 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 8,356,139 shares (-32.1%) from their portfolio in Q3 2024, for an estimated $14,205,436
- MILLENNIUM MANAGEMENT LLC added 5,792,951 shares (+125.1%) to their portfolio in Q3 2024, for an estimated $9,848,016
- BANK OF NEW YORK MELLON CORP removed 4,362,004 shares (-43.9%) from their portfolio in Q3 2024, for an estimated $7,415,406
- EDMOND DE ROTHSCHILD HOLDING S.A. added 3,571,460 shares (+21.3%) to their portfolio in Q3 2024, for an estimated $6,071,482
- JACKSON SQUARE PARTNERS, LLC removed 2,587,327 shares (-29.1%) from their portfolio in Q3 2024, for an estimated $4,398,455
- SUMITOMO MITSUI TRUST GROUP, INC. removed 1,687,265 shares (-14.2%) from their portfolio in Q4 2024, for an estimated $3,087,694
- D. E. SHAW & CO., INC. removed 1,645,499 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $2,797,348
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in Nature Genetics . The study, titled Synchronized long-read genome, methylome, epigenome, and transcriptome for resolving a Mendelian condition , showcases how researchers leveraged PacBio’s advanced sequencing solutions, including the synchronized Fiber-seq and Kinnex (formerly MAS-seq) multiomic approach, to uncover the genetic and molecular basis of a rare and complex Mendelian condition.
In collaboration with the University of Washington and the Undiagnosed Diseases Network (UDN), the study applied PacBio’s state-of-the-art Revio™ sequencing system to integrate long-read genomic, transcriptomic, methylomic, and epigenomic data in a synchronized analysis to analyze a 9-month-old patient with an unsolved condition involving bilateral retinoblastomas, developmental delays, and additional symptoms. Previous diagnostic methods, including short-read sequencing, were unable to provide an answer. With PacBio’s innovative multiomic solutions, researchers identified a chromosome X;13 balanced translocation disrupting four key genes—each through a unique molecular mechanism.
"This study highlights the power of highly accurate long-read multiomic sequencing in understanding the genetic mechanisms behind complex rare diseases," said Andrew B. Stergachis, MD, PhD, senior author and associate professor at the University of Washington. "By integrating genomic, transcriptomic, epigenomic, and methylomic data in a single analysis, we were able to pinpoint multiple molecular disruptions contributing to this rare Mendelian condition—findings that would have been impossible with traditional approaches."
Key Findings Enabled by PacBio Technology:
- Synchronized Multiomic Sequencing : For the first time, a single sequencing run provided simultaneous insights into genome, methylome, epigenome, and transcriptome data, eliminating the need for redundant experiments.
- Resolution of Complex Mechanisms : PacBio’s long-read accuracy uncovered a range of pathogenic events, including fusion transcripts, enhancer adoption, transcriptional readthrough silencing, and epigenetic disruptions—offering a complete genomic picture of the disease.
-
Haplotype-Specific Insights
: The technology allowed precise phasing of genetic, epigenetic, and transcriptomic features, crucial for understanding the functional impact of rare variants.
“This is the kind of transformative research we’re passionate about enabling,” said David Miller, Vice President of Global Marketing at PacBio. “The ability to replace multiple legacy assays and simultaneously analyze the genome, methylome, epigenome, and transcriptome in high resolution is a testament to how far HiFi sequencing technology has come. With the latest Revio system and SPRQ chemistry updates launched at ASHG, scientists now have the tools to uncover answers that were previously out of reach. It’s thrilling to see this technology driving real-world impact.”
This study, spearheaded by a team of renowned researchers including Mitchell R. Vollger, Andrew B. Stergachis, and others, highlights the collaboration between leading institutions such as the University of Washington Center for Mendelian Genomics (UW-CMG) and the Undiagnosed Diseases Network (UDN). Their collective expertise is helping shape the future of genomics, advancing the ability of health care providers to diagnose and treat rare genetic diseases.
The findings are available here .
For more information on how PacBio’s Revio system is redefining multiomics research, visit pacb.com/revio .
About Pacific Biosciences
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements
:
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, coverage, advantages, and benefits or expected benefits of using, PacBio products or technologies, including researchers’ ability to help shape the future of genomics and advance the ability of health care providers to diagnose and treat rare genetic diseases; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, the difficulty of generating discoveries in complicated areas of biology; potential performance, quality and regulatory issues; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
PacBio
For investors:
Todd Friedman,
[email protected]
For media:
[email protected]